Current therapeutic strategies for myalgic encephalomyelitis/chronic fatigue syndrome: results of an online survey

A new paper co-authored by Biovista and the Solve ME/CFS Initiative has just been published. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, poorly understood disorder that causes only a small number of the approximately 2.5 million Americans to receive proper diagnosis. Given the multitude of symptoms that patients with ME/CFS experience, treatment approaches have been wide-ranging, as no medications for its treatment have been approved by the US Food and Drug Administration (FDA) to date.

This paper presents a survey of international ME/CFS expert clinicians that we conducted in order to record the treatment strategies they employed and the subpopulations of patients where they deem particular treatments to be appropriate. The survey aimed at identifying current best practices for the treatment of ME/CFS, which were then compared with the drug candidates identified through Biovista’s repurposing platform.

This publication can be accessed here.